Company Reports Q1 Revenue of $164.9M, Below Expectations
Reports Q1 revenue $164.9M, consensus $186.6M. "This quarter's results include a significant milestone: With the FDA's approval of Lifyorli (relacorilant) to treat women with platinum-resistant ovarian cancer more than three months before its PDUFA date, this is the last quarter for which our financial results will reflect the sales of just one medication. In April, Lifyorli, in combination with nab-paclitaxel, was added to NCCN Guidelines(R) as a preferred regimen and uptake has been vigorous. In February, our Cushing's syndrome business completed its transition to our new pharmacy vendor, which is successfully fulfilling the increasing demand for Korlym and our authorized generic. March and April marked all-time highs in the number of patients starting treatment."
